Stoke Therapeutics (STOK) Revenue (2022 - 2026)

Stoke Therapeutics' Revenue history runs 5 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• In Q1 2026, Revenue fell 96.07% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $32.1 million (down 83.2% YoY), while the FY2025 annual figure was $184.4 million, up 404.5% from the prior year.
• Revenue for Q1 2026 stood at $6.2 million, up from $1.4 million in the prior quarter.
• The five-year high for Revenue was $158.6 million in Q1 2025, with the low at $1.4 million in Q4 2025.
• The 5-year median for Revenue is $4.2 million (2024), against an average of $14.9 million.
• The sharpest annual moves came in 2025 and 2026: Revenue soared 3661.12% in 2025, then sank 96.07% in 2026.
• Stoke Therapeutics' Revenue stood at $3.3 million in 2022, then fell by 14.26% to $2.8 million in 2023, then surged by 707.07% to $22.6 million in 2024, then plunged by 93.8% to $1.4 million in 2025, then surged by 344.29% to $6.2 million in 2026.
• Business Quant data shows STOK's Revenue at $6.2 million in Q1 2026, $1.4 million in Q4 2025, and $10.6 million in Q3 2025.